Introduction
============

Gastroesophageal reflux disease (GERD) is a common disorder with the classical symptoms being heartburn and regurgitation, and the less common symptoms including dysphagia, laryngitis, asthma and chest pain ([@b12]). Early data (1976) from the US suggested that 7% of the adult population experienced symptoms daily and around 36% had these symptoms at least once a month ([@b22]). These data are likely to be the source of the commonly quoted figure of almost 40% of adults experiencing these symptoms. However, a more recent study found that 22% of American adults reported daily symptoms of heartburn and 57% reported such symptoms at least weekly ([@b25]). Due to the differences in study methodology, it remains unclear whether or not these two studies actually demonstrate an increase in incidence of GERD over the 20 year interval. In Australia, results of a telephone survey in New South Wales seeking information about symptoms of dyspepsia in the previous three months reported a prevalence of 11.4% to 36% depending on the definition used ([@b30]). Another Australia-wide telephone survey found that 37% of respondents reported experiencing heartburn at least once every 4--6 months ([@b2]).

While the symptoms of GERD are painful and debilitating for the patient, reflux is a serious disorder because it is associated with the development of Barrett\'s esophagus and adenocarcinoma of the esophagus and gastric cardia ([@b4]). The aetiology of Barrett\'s esophagus, a metaplastic process in which native squamous epithelium of the distal esophagus is replaced by columnar epithelium, is unknown, however, clinical and experimental data implicate GERD ([@b24]). There is evidence for a "probably causal" relationship between GERD and adenocarcinoma of the esophagus, with less clear evidence of a link between reflux and adenocarcinoma of the gastric cardia ([@b16]).

The incidence of these two cancers (adenocarcinoma of the esophagus and gastric cardia) is rising faster than that of any other cancer in the US ([@b6]). In addition, an 8-fold increase in esophageal adenocarcinoma has been reported in Denmark between 1970 and 1990. This increase was not explained by changes in classification or diagnosis ([@b3]). The incidence of this cancer is also rising in Australia ([@b17]). The reason for the increasing incidence of these cancers is unclear ([@b8]). However, the likely increase in the prevalence of GERD, the increase in obesity ([@b18]), and the decline in *Helicobacter pylori* colonisation (associated with lower birth rates and the use of antibiotics, together with a change in the number and type of variants of the bacterium; [@b1]) have been suggested as possible causes.

The mechanisms resulting in GERD are complex and affected by many factors including the anatomy, genetics and environment of the individual ([@b29]). Many studies have investigated the effects of individual dietary components on normal volunteers and people with GERD ([@b10]; [@b11]; [@b27], [@b26]; [@b21]; [@b5]). However the results of such studies remain contradictory.

A review of the earlier literature concluded that lifestyle modifications have been shown to be effective in the treatment of GERD ([@b15]), however, there have been few well-designed placebo-controlled trials. Subsequently it has been suggested that many of these lifestyle changes would not be of benefit in alleviating the symptoms of GERD, although they would be appropriate for promoting general health ([@b9]). A more recent review has identified lifestyle recommendations which are likely to be effective and those with little supporting evidence ([@b19]).

Considerable debate remains about the type of treatment that should be recommended for the disease, with these discussions focusing mostly on medication and surgery ([@b13]) with little mention of lifestyle modification. Although conservative therapy (diet, posture, antacids), was the only treatment for GERD until the advent of the antisecretory drugs, the current usage and associated success rate is unknown. Lifestyle treatment of GERD, in addition to medication, is recommended in both Australia ([@b14]) and US ([@b7]) and its use has been documented in studies of general practitioners in Germany ([@b20]) and Australia ([@b23]). Such advice has been provided "despite the lack of scientific evidence" ([@b20]). Furthermore, participants in a US study investigating the perceived effects of dietary intake on symptoms of 'heartburn' among 2000 individuals identified a number of foods which they believed precipitated their GERD symptoms ([@b25]).

Our clinical experience has implicated similar dietary factors and suggested that lifestyle modification may reduce both the symptoms of GERD and patient reliance on medication to treat this disorder. We retrospectively evaluated the outcome of this treatment among patients attending a dietetic practice over a three-year period.

Methods and materials
=====================

Participants
------------

All records of adult patients presenting to one private dietetic practice in Townsville (approximately 130 000 inhabitants), Australia, between 1 July 1999 and 30 June 2002 were examined retrospectively in August 2002. Patients who presented either specifically for the treatment of GERD symptoms, or who complained of GERD symptoms during a consultation for another disorder were considered for this case series. However, only those patients who had attended an initial dietetic consultation and at least one review were included in the case series (n=24). One patient, who was initially included, was subsequently found to have been prescribed a proton pump inhibitor between the two dietetic consultations and was therefore excluded.

Intervention
------------

In this practice, all patients who mention heartburn, reflux, indigestion, or esophagitis are routinely given standardized dietary and postural advice to alleviate GERD symptoms as a first line of treatment. This advice includes: not reclining within two to three hours of eating; a diet low in fat; small frequent meals; avoiding dietary components considered to relax the lower esophageal sphincter; and avoiding local irritants (eg, citrus juices, tomato concentrates, and spices) ([@b31]). It is suggested that these modifications be adhered to rigorously for one month, followed by a careful trial of individual components to identify those that should be excluded in future.

Data collection
---------------

Data collected from standard patient records included, sex, age, height, weight, medication, number of consultations, time between the first and the last consultation, use of alcohol and tobacco, exercise level, dietary intake, GERD symptoms, and comorbidities. As patients had routinely been asked open ended questions about their reflux symptoms, their subjective responses were also collected from the patient records. Patients were not systematically questioned about prior endoscopies, but for the purposes of this case series were considered to not have undergone an endoscopy if it was not mentioned either by the referring doctor or by the patient during the consultation. Patients were asked to self-report the frequency and severity of GERD symptoms and the use of GERD medication.

Statistical analysis
--------------------

Data were analysed using SPSS for Windows, release 6.3. Numerical data were described using mean and standard deviation (SD) or median and interquartile range, as appropriate. Valid percentages (ie, percentages calculated by excluding patients with missing information) were given for categorical variables. Comparisons between gender were conducted using Chi-square tests (asymptotic and exact), Fisher\'s exact test, t-tests, and non-parametric Wilcoxon tests, as appropriate. Frequency (none, occasional, less than daily, daily) and severity (none, mild, moderate, severe) of symptoms were assessed at initial presentation and after treatment and were tested for significant changes using exact paired McNemar tests. Changes in weight and body mass index were assessed using paired non-parametric Wilcoxon tests.

Results
=======

A total of 23 patients (12 males) were included in the present case series. The mean age of these patients was 50.2 years (SD±12.6 years) with the age distribution being five between 20 and 39 years (4 female), 14 between 40 and 59 years (4 female), and four were at least 60 years old (3 female). The majority of patients had been referred to the dietetic clinic by a general practitioner (n=18), had previously had an endoscopy (n=13), had comorbidities at presentation (n=19), and were taking medication to relieve GERD symptoms at presentation (n=18) ([Table 1](#tbl1){ref-type="table"}). Females were more likely than males to present specifically for the treatment of GERD symptoms (p=0.003), and to have had an endoscopy (p=0.019) ([Table 1](#tbl1){ref-type="table"}). The median alcohol intake was 0.5 standard drinks per day with interquartile range (IQR) 0.05--2.1 and range 0--20.

###### 

Characteristics of 23 adult patients with gastroesophageal reflux disease (GERD) attending a dietetic practice in Townsville, Australia

                                                                                                                 Total (n=23)          Male (n=12)           Female (n=11)                               p-value[a](#tf1-1){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------------------- --------------------- --------------------- ------------------------------------------- ------------------------------------------
  **Baseline characteristics**                                                                                                                                                                           
  Mean age (± SD[b](#tf1-2){ref-type="table-fn"}) in years                                                       50.2 (12.6)           50.8 (6.1)            49.5 (17.5)                                 p=0.832
  Referred by general practitioner                                                                               18 (78.2%)            9 (75.0%)             9[d](#tf1-4){ref-type="table-fn"} (81.8%)   p=1[e](#tf1-5){ref-type="table-fn"}
  Presented for:                                                                                                                                                                                         
   GERD alone                                                                                                    7 (30.4%)             1 (8.3%)              6 (54.5%)                                   
   GERD plus other disease                                                                                       7 (30.4%)             3 (25.0%)             4 (36.4%)                                   
   Incidentally mentioned GERD                                                                                   9 (39.1%)             8 (66.7%)             1 (9.1%)                                    p=0.003 [e](#tf1-5){ref-type="table-fn"}
  History of endoscopy                                                                                           13 (56.5%)            4 (33.3%)             9 (81.8%)                                   p = 0.019
  Using GERD medication at presentation                                                                          18 (85.7%)            7 (70.0%)             11 (100%)                                   p=0.090 [e](#tf1-5){ref-type="table-fn"}
  Comorbidities at presentation                                                                                  19 (82.6%)            12 (100%)             7 (63.6%)                                   p=0.037 [e](#tf1-5){ref-type="table-fn"}
  Number of patients consuming \>I standard alcoholic drink/day (1 missing)                                      6 (27.3%)             4 (33.3%)             2 (20.0%)                                   p=0.646 [e](#tf1-5){ref-type="table-fn"}
  Number of smokers (5 missing)                                                                                  2 (11.1%)             1 (12.5%)             1 (10.0%)                                   p=1 [e](#tf1-5){ref-type="table-fn"}
  Median body mass index at initial presentation (kg/m^2^) \[IQR\][c](#tf1-3){ref-type="table-fn"} (5 missing)   30.1 \[26.8, 32.5\]   30.2 \[27.3, 33.5\]   28.0 \[24.3, 31.6\]                         p=0.201 [e](#tf1-5){ref-type="table-fn"}
  **Treatment**                                                                                                                                                                                          
  Median number of visits \[IQR\]                                                                                2 \[2, 5\]            2 \[2, 5.25\]         3 \[2, 5\]                                  p=0.608 [e](#tf1-5){ref-type="table-fn"}
  Median period of visits \[IQR\] in months                                                                      1.5 \[1.0, 7.0\]      1.3 \[1.0, 5.9\]      2 \[1.3, 7.0\]                              p=0.347 [e](#tf1-5){ref-type="table-fn"}
  **Outcome**                                                                                                                                                                                            
  Number of patients with reduction in frequency of symptoms                                                     19 (90.5%)            11 (91.7%)            8 (88.9%)                                   p=1[e](#tf1-5){ref-type="table-fn"}
  Number of patients with reduction in severity of symptoms                                                      10 (47.6%)            7 (58.3%)             3 (33.3%)                                   p=0.387 [e](#tf1-5){ref-type="table-fn"}
  Decrease in medication (number and/or type)[f](#tf1-6){ref-type="table-fn"}                                    11 (73.3%)            3 (60.0%)             8 (80.0%)                                   p=0.560 [e](#tf1-5){ref-type="table-fn"}
  Median weight change[g](#tf1-7){ref-type="table-fn"} (kg) \[IQR\]                                              −1.5 \[−3.6, 0.0\]    −3.0 \[−5.5, −0.5\]   −1.0 \[−2.8, 0.5\]                          p=0.165 [e](#tf1-5){ref-type="table-fn"}

**Notes:** p-value relates to comparison between the genders;

SD, standard deviation;

IQR, inter-quartile range;

One patient presented following a suggestion from a GP (not her own GP) in a social situation;

p-value result of exact test;

Data on medication was available for 15 patients at initial presentation and after treatment;

Weight data available for 18 patients.

More males than females presented with comorbidities (p=0.037), with the most common comorbidities being obesity, hyperlipidemia, and hypertension ([Table 2](#tbl2){ref-type="table"}). The majority of the patients were taking prescribed medication for GERD (n=15) with an additional three taking over the counter medication for this disease (21 patients with valid information) ([Table 2](#tbl2){ref-type="table"}).

###### 

Medication and comorbidities at initial presentation of 23 adult patients with gastroesophageal reflux disease (GERD) attending a dietetic practice in Townsville, Australia

                                                                                                                          Total (n = 23)   Male(n = 12)   Female(n = 11)
  ----------------------------------------------------------------------------------------------------------------------- ---------------- -------------- ----------------
  **GERD medication[a](#tf2-1){ref-type="table-fn"}**                                                                                                     
  Number of patients using GERD medication at presentation                                                                18 (85.7%)       7 (70.0%)      11 (100%)
  Number of patients using antacids                                                                                       2 (9.5%)         1 (10.0%)      1 (9.1%)
  Number of patients using alginates                                                                                      1 (4.8%)         1 (10.0%)      0
  Number of patients using H2-antagonists                                                                                 11 (52.4%)       4 (40.0%)      7 (63.6%)
  Number of patients using proton pump inhibitors                                                                         5 (23.8%)        1 (10.0%)      4 (36.4%)
  **Comorbidities[b](#tf2-2){ref-type="table-fn"}**                                                                                                       
  Number of overweight patients[c](#tf2-3){ref-type="table-fn"} (BMI[d](#tf2-4){ref-type="table-fn"} ≥ 25 and BMI ≤ 30)   6 (30.0%)        2 (18.2%)      4 (44.4%)
  Number of obese patients[c](#tf2-3){ref-type="table-fn"} (BMI \> 30)                                                    11 (55.0%)       8 (72.7%)      3 (33.3%)
  Number of patients with hypertension                                                                                    8 (34.8%)        5 (41.7%)      3 (27.2%)
  Number of patients with hyperlipidemia                                                                                  12 (52.2%)       9 (75.0%)      3 (27.2%)
  Number of patients with history of coronary artery bypass surgery                                                       2 (8.7%)         2 (16.7%)      0 (0.0%)
  Number of patients with non-insulin dependent diabetes mellitus or impaired glucose tolerance                           4 (17.4%)        3 (25.0%)      1 (9.0%)
  Number of patients with diverticulitis or "bowel problems"                                                              4 (17.4%)        3 (25.0%)      1 (9.0%)
  Number of patients with chronic pain                                                                                    2 (8.7%)         2 (16.7%)      0 (0.0%)
  Number of patients with post traumatic stress disorder                                                                  3 (13.0%)        3 (25.0%)      0 (0.0%)
  Number of patients with gout                                                                                            1 (4.3%)         1 (8.3%)       0 (0.0%)
  Number of patients with asthma                                                                                          1 (4.3%)         0 (0.0%)       1 (9.0%)
  Number of patients with osteoporosis                                                                                    1 (4.3%)         0 (0.0%)       1 (9.0%)
  Number of patients with migraines                                                                                       1 (4.3%)         1 (8.3%)       0 (0.0%)

**Notes:** Some patients presented using more than one medication; information given is based on 21 patients;

Some patients had multiple comorbidities;

Weight was unavailable for 3 patients;

BMI, body mass index (kg/m^2^).

At initial presentation, 13 of 21 patients with valid information reported daily symptoms of GERD with eight reporting less frequent symptoms. Of those 21 patients, 18 classified their symptoms as severe and three as moderate.

All but one patient reported a decrease in frequency and/or severity of symptoms following treatment. This exception was a 79 year old female with a body mass index of 17.2 kg/m^2^, who presented specifically because of GERD which had been confirmed at endoscopy. She was taking a proton pump inhibitor (twice daily) to treat the following symptoms, which she had had for more than 30 years: nausea; reflux cough; hoarse voice; regular burping, and flatulence; and occasional central upper abdominal pain. After a rigorous trial of the "reflux" diet she reported no change in either symptoms or the use of medication.

Of the remaining 22 patients, eight (3 female) were completely symptom free following treatment; eight (5 female) reported only having symptoms of GERD when they "broke the lifestyle rules"; and five (1 female) reported a reduction in the frequency and/or severity of their GERD symptoms following treatment. The specific symptoms of one patient were not recorded, although she reported marked improvement at her review appointment. Overall, frequency (p\<0.001) and severity (p=0.002) of symptoms improved after treatment.

Of the 18 patients for whom weight data were available at initial and final presentation, 12 had lost weight, 3 had gained weight, and 3 had remained the same weight, with the range of weight change being −8 kilograms to +2 kilograms ([Table 1](#tbl1){ref-type="table"}). Weight (p=0.007) was significantly reduced after treatment. There were no significant differences in overall improvement (p=0.3330) or frequency of symptoms (p=0.5908) between patients who had lost weight during the treatment period and those who had not. However, patients who had lost weight during the treatment period were more likely to experience less severe GERD symptoms than those who had not lost weight (p=0.0365).

Eleven of the 18 patients who were taking GERD medication at presentation reported a reduction in the use of GERD medication, although there was no encouragement given during consultations for patients to reduce either the type or quantity of GERD medication.

Discussion
==========

The results of this case series suggest that lifestyle modification may have at least an adjunct role to play in the treatment of GERD. All but one of the patients reported a reduction in GERD symptoms following a rigorous trial of lifestyle modification, with the majority reporting either no symptoms or only occasional symptoms for which they could identify the cause. In addition, more than half the patients who were using medication for the treatment of GERD had also reduced the type or frequency of medication.

The literature contains many reports of studies specifically examining the effects of weight loss, fat intake, and many of the local irritants incorporated into the advice given to these patients ([@b15]). These studies have examined dietary components individually and have been conducted rigorously, but the results have not been consistent ([@b19]). The patients reported here have been treated quite differently, with all components of lifestyle modification being tested for weeks rather than individual components being tested for hours. Furthermore, the endpoint in this work was patient symptoms whereas most studies have examined the effect on the lower esophageal sphincter or esophageal pH ([@b10]; [@b11]; [@b27], [@b26]; [@b5]). It is thus difficult to make any comparisons between the results obtained from these patients and the results of previously published studies.

Some reflux symptoms have been shown to be associated with obesity ([@b28]) and weight loss is generally considered to reduce the symptoms of GERD ([@b15]; [@b19]). Yet, among these patients, there did not appear to be any difference in the overall effect of treatment on symptoms between those who had lost weight, those who had gained weight, or remained the same. However, those who had lost weight did report a decrease in the severity, but not frequency, of symptoms. As there were only a small number of participants in this study, it is not possible to determine whether weight loss or the lifestyle changes leading to weight loss were responsible for the improvement in symptoms. For many of these patients reducing the symptoms of GERD was far more important than weight loss, thus weight loss occurred almost as a consequence of treatment for GERD. Thus careful questioning about symptoms of GERD by clinicians, and encouraging treatment of these symptoms by lifestyle modification may act as a motivator to change to more healthful dietary behavior.

This case series included a carefully selected group of patients, either selected by their doctors, or self selected. The grounds for selection were probably: being prepared to consider lifestyle modification for treatment of disease; placing a high priority on health therefore being prepared to attend a private dietetic practice; and preferring not to take medication if it could be avoided. Only those patients who returned for review were included. Hence, these patients may have been particularly motivated and thus not representative of the wider population suffering from GERD. It is certainly possible that a number of patients who derived no benefit from treatment chose not to return for review and thus this case series may represent a "best case scenario".

As the results are based on a small number of cases, they should be interpreted with caution. Nevertheless, this case series has shown encouraging results and indicates that a randomized controlled intervention to fully evaluate the efficacy of lifestyle modification in the treatment of symptoms of GERD is probably justified.

Funding for this work was provided by the Queensland Cancer Fund, the Parkes Bequest (James Cook University), and Queensland Health. Madeleine Nowak is supported by a Research Fellowship from the Queensland Cancer Fund, and Simone Harrison is supported by a Research Fellowship from Queensland Health.
